[Correspondence] Clinical benefits of selumetinib in adults with neurofibromatosis type 1 – Authors' reply

We acknowledge the observations raised by Suyin Feng and colleagues. KOMET,1 the first global, randomised, placebo-controlled trial represents a landmark achievement demonstrating selumetinib efficacy and safety in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The sample size and methodological robustness enabled clear conclusions about the positive effect of selumetinib on volume and pain of plexiform neurofibromas.1